...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS >Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients
【24h】

Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients

机译：幼稚艾滋病患者治疗中的比较疗效与安全性和氯卓血管

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Compare the efficacy and safety of the 2-drug antiretroviral therapy regimen dolutegravir + lamivudine (DTG + 3TC) with traditional 3-drug regimens in treatment-naive patients with HIV-1. Design: Data from double-blind, randomized controlled trials of at least 48 weeks' duration in treatment-naive patients with HIV-1 identified by systematic review were evaluated using a Bayesian network meta-analysis methodology. Methods: The primary outcome was virologic suppression at Week 48 for 3-drug regimens versus DTG + 3TC (also analyzed in patient subgroup with baseline viral load >100 000 RNA copies/ml). Secondary outcomes included CD4(+) cell count change from baseline and safety (adverse events, serious adverse events, and drug-related adverse events) at Week 48. Results: The network contains 14 unique regimens from 14 randomized controlled trials based on data from 10 043 patients. The proportional difference for viral suppression at 48 weeks for DTG + 3TC versus the other 13 regimens included in the network ranged from -2.7% (-11.0, 5.6%) versus DTG + tenofovir alafenamide/emtricitabine (FTC) to 7.3% (0.6, 13.8%) versus efavirenz + tenofovir disoproxil fumarate/FTC. DTG + 3TC was found to be significantly better than efavirenz + tenofovir disoproxil fumarate/FTC and similar to all other regimens analysed in terms of viral suppression at 48 weeks. With regard to other outcomes (CD4(+), adverse event, serious adverse event, drug-related adverse events) at 48 weeks, DTG+3TC was broadly similar to all regimens analysed. Conclusion: This network meta-analysis demonstrates similar efficacy and safety outcomes over 48 weeks with DTG + 3TC compared with traditional 3-drug antiretroviral therapy regimens.
机译：目的：比较2-药物抗逆转录病毒治疗方案DoluteGravir +拉米夫定（DTG + 3TC）与HIV-1治疗幼虫治疗患者的传统3-药物方案的疗效和安全性。设计：使用贝叶斯网络Meta分析方法评估了通过系统审查所鉴定的治疗NIV-1患者的双盲，随机对照试验中的数据至少48周的持续时间。方法：在3-药物方案与DTG + 3TC中，主要结果是病毒学抑制，而DTG + 3Tc（也在患者亚组中分析基线病毒载荷> 100 000RNA拷贝/ mL）。次要结果包括第48周的基线和安全（不良事件，严重的不良事件和药物相关不良事件的CD4（+）细胞计数。结果：网络含有14个基于14项随机对照试验的独特方案，基于数据10 043患者。对于DTG + 3TC的48周的病毒抑制比例差异与网络中包含的其他13个方案范围为-2.7％（-11.0,5.6％），与DTG + Tenofovir Alafenamide / Emtrickabine（FTC）相比为7.3％（0.6， 13.8％）与efaviraz +替诺福韦解毒型富马酸盐/ FTC。发现DTG + 3TC明显优于EFAVIRENZ + Tenofovir Disoproxil umarate / FTC，并且类似于在48周的病毒抑制方面进行分析的所有其他方案。关于其他结果（CD4（+），不良事件，严重不良事件，药物相关不良事件）在48周时，DTG + 3TC与分析的所有方案相似。结论：该网络荟萃分析与传统的3-药物抗逆转录病毒治疗方案相比，DTG + 3TC与DTG + 3TC有超过48周的类似疗效和安全结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号